HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.

ABSTRACT:

Introduction

We have previously linked HER4 expression with increased survival in breast cancer. However, other reports have associated HER4 with adverse prognostic significance. One possible explanation for the conflicting reports may be that these results are antibody dependent. The HER4 protein is enzymatically cleaved, which may alter the function of its intracellular domain (ICD). We have therefore compared the staining patterns of antibodies against its intracellular and extracellular domains using tissue microarray technology.

Methods

Immunohistochemistry was performed and evaluated on tumours from 402 tamoxifen treated oestrogen receptor positive patients. The HFR1 antibody recognises the ICD of HER4 and thus recognises both the intact receptor and the cleaved ICD. T

SUBMITTER: Tovey SM 

PROVIDER: S-EPMC1557726 | biostudies-literature | 2006

REPOSITORIES: biostudies-literature